The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late July 2020 when we will write to you about how you can get involved.